← Back to home

EBV+ LYMPHOPROLIFERATIVE DISEASE WITH ACQUIRED (NON-CONGENITAL) IMMUNODEFICIENCY (EBV+ AID LPD)

Clinical trials for EBV+ LYMPHOPROLIFERATIVE DISEASE WITH ACQUIRED (NON-CONGENITAL) IMMUNODEFICIENCY (EBV+ AID LPD) explained in plain language.

Never miss a new study

Get alerted when new EBV+ LYMPHOPROLIFERATIVE DISEASE WITH ACQUIRED (NON-CONGENITAL) IMMUNODEFICIENCY (EBV+ AID LPD) trials appear

Sign up with your email to follow new studies for EBV+ LYMPHOPROLIFERATIVE DISEASE WITH ACQUIRED (NON-CONGENITAL) IMMUNODEFICIENCY (EBV+ AID LPD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Experimental cell therapy targets dangerous virus in vulnerable patients

Disease control Recruiting now

This study is testing whether an experimental cell therapy called tabelecleucel can help control diseases caused by the Epstein-Barr virus in people with weakened immune systems. The trial includes 190 participants who have developed serious conditions like lymphomas or sarcomas …

Matched conditions: EBV+ LYMPHOPROLIFERATIVE DISEASE WITH ACQUIRED (NON-CONGENITAL) IMMUNODEFICIENCY (EBV+ AID LPD)

Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control

Last updated Mar 12, 2026 13:52 UTC

EBV+ LYMPHOPROLIFERATIVE DISEASE WITH ACQUIRED (NON-CONGENITAL) IMMUNODEFICIENCY (EBV+ AID LPD)

Get alerted when new EBV+ LYMPHOPROLIFERATIVE DISEASE WITH ACQUIRED (NON-CONGENITAL) IMMUNODEFICIENCY (EBV+ AID LPD) trials appear

Experimental cell therapy targets dangerous virus in vulnerable patients